Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 19, 2026, 10:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 282 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: rhGH Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of Syntropin (Human Growth Hormone) for the Treatment of Growth Hormone Deficiency

NCT00489294
View directory record Official record
Conditions
Growth Hormone Deficiency
Interventions
Syntropin
Drug
Lead sponsor
Phage Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 11, 2012 · Synced Sep 19, 2026, 10:48 PM EDT
Not listed Phase 1Phase 2 Interventional

Human Growth Hormone Pre-treatment for 6 Weeks Prior to Ovulation Induction for IVF

NCT02179255
View directory record Official record
Conditions
Female Infertility Due to Diminished Ovarian Reserve
Interventions
Human Growth Hormone, Follicle Stimulating Hormone
Drug
Lead sponsor
Center for Human Reproduction
Other
Eligibility
18 Years to 44 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 17, 2020 · Synced Sep 19, 2026, 10:48 PM EDT
Terminated Phase 2Phase 3 Interventional

Assessment of the Treatment of Severely Burned With Anabolic Agents on Clinical Outcomes, Recovery and Rehabilitation

NCT00675714
View directory record Official record
Conditions
Burns
Interventions
Stable Isotope Infusion Study, Collection of blood and tissues, Radiology testing: Dual-energy X-ray absorptiometry (DEXA), ultrasound, MRI, Humatrope, Ketoconazole, Oxandrolone, Propranolol, Oxandrolone and propranolol combined, Humatrope and propranolol combined, Placebo, Exercise--Hospital supervised intensive exercise program, Home exercise program
Procedure · Drug · Behavioral
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
Up to 80 Years
Enrollment
1,126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2019
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 28, 2019 · Synced Sep 19, 2026, 10:48 PM EDT
Completed Phase 3 Interventional Results available

Aromatase Inhibitors, Alone And In Combination With Growth Hormone In Adolescent Boys With Idiopathic Short Stature

NCT01248416
View directory record Official record
Conditions
Idiopathic Short Stature
Interventions
Aromatase Inhibitor, Growth Hormone, Aromatase Inhibitor and Growth Hormone
Drug
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
12 Years to 18 Years · Male only
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
3
States / cities
Jacksonville, Florida • Orlando, Florida • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 6, 2018 · Synced Sep 19, 2026, 10:48 PM EDT
Terminated Phase 3 Interventional Results available

Study of TV-1106 in Growth Hormone-Deficient Adults

NCT02410343
View directory record Official record
Conditions
Growth Hormone Deficiency
Interventions
TV-1106, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
25
States / cities
Artesia, California • Fountain Valley, California • Miami, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2022 · Synced Sep 19, 2026, 10:48 PM EDT
Recruiting Phase 1 Interventional

AAVrh10-PCCA Gene Therapy for Propionic Acidemia

NCT07643844
View directory record Official record
Conditions
Propionic Acidemia
Interventions
AAVrh10-PCCA low dose, AAVrh10-PCCA middle dose, AAVrh10-PCCA high dose
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
6 Months to 2 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 19, 2026, 10:48 PM EDT
Withdrawn Not applicable Interventional

Effects of Growth Hormone in Chronically Ill Children

NCT00286689
View directory record Official record
Conditions
Hurler Syndrome, Cerebral Palsy, Juvenile Rheumatoid Arthritis, Crohn Disease, HIV Infections
Interventions
Growth Hormone, Whole body Protein turnover, DEXA scan
Drug · Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
3 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 13, 2018 · Synced Sep 19, 2026, 10:48 PM EDT
Active, not recruiting Phase 2 Interventional Results available

A Research Study in Children Born Small and Who Stayed Small. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day

NCT03878446
View directory record Official record
Conditions
Short Stature Children Born Small for Gestational Age (SGA)
Interventions
Somapacitan, Norditropin®
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
2 Years to 11 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
14
States / cities
Birmingham, Alabama • Orange, California • Boise, Idaho + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 19, 2026, 10:48 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety of an Oral Growth Hormone Drug in the Treatment of Fibromyalgia

NCT00116129
View directory record Official record
Conditions
Fibromyalgia
Interventions
Ibutamoren Mesylate (MK-0677)
Drug
Lead sponsor
Bennett, Robert, M.D.
Individual
Eligibility
30 Years to 65 Years · Female only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 5, 2012 · Synced Sep 19, 2026, 10:48 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Effects of GH and Lirglutide on AgRP

NCT05681299
View directory record Official record
Conditions
Healthy, Growth Hormone Deficiency
Interventions
growth hormone and lirglutide, growth hormone, liraglutide, Placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Sep 19, 2026, 10:48 PM EDT
Not listed Phase 2 Interventional

Study of Weekly ALTU-238 Compared With Daily Nutropin AQ in Prepubertal Children With Growth Hormone Deficiency

NCT00837863
View directory record Official record
Conditions
Growth Hormone Deficiency
Interventions
Somatropin
Drug
Lead sponsor
Altus Pharmaceuticals
Industry
Eligibility
3 Years to 13 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
11
States / cities
Little Rock, Arkansas • Orlando, Florida • Springfield, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated May 6, 2009 · Synced Sep 19, 2026, 10:48 PM EDT
Terminated No phase listed Observational Results available

A Study to Evaluate Growth in Participants Treated With Somatropin (Nutropin) Using NuSpin Device

NCT01243892
View directory record Official record
Conditions
Growth Hormone Deficiency
Interventions
NuSpin, Somatropin
Device · Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
2 Years to 14 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
14
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Sacramento, California + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2016 · Synced Sep 19, 2026, 10:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Testosterone-Driven Growth-Hormone (GH) Secretion in Aging Men

NCT00309855
View directory record Official record
Conditions
Aging
Interventions
Placebo, Testosterone, Anastrazole, Dutasteride
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
50 Years to 80 Years · Male only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 30, 2012 · Synced Sep 19, 2026, 10:48 PM EDT
Completed Phase 3 Interventional

Somatropin Treatment in Patients With SHOX Deficiency and Turner Syndrome

NCT00190658
View directory record Official record
Conditions
Failure to Thrive
Interventions
Somatropin (rDNA origin) for injection
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
3 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 19, 2010 · Synced Sep 19, 2026, 10:48 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Chromosome 18 Clinical Research Center

NCT00227253
View directory record Official record
Conditions
Chromosome Aberrations, Growth Hormone Deficiency, Hypomyelination
Interventions
Determination of growth hormone status, Measurement of growth, thyroid and sex hormone levels, Behavior and neuropsychometric evaluations, Audiological and ear, nose and throat examination, Magnetic resonance imaging of the brain, Dysmorphology evaluation, Neurology examination, Dental evaluation, Speech pathology evaluation, Psychiatric evaluation, Orthopedic evaluation, Ophthalmologic evaluation, Gastrointestinal evaluation
Procedure
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
Not listed
Enrollment
4,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1993 – 2040
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 5, 2026 · Synced Sep 19, 2026, 10:48 PM EDT
Recruiting No phase listed Observational

A US Non-interventional, Effectiveness and Safety Study of Patients Treated With SKYTROFA

NCT05820672
View directory record Official record
Conditions
Growth Hormone Deficiency
Interventions
No intervention
Other
Lead sponsor
Ascendis Pharma Endocrinology Division A/S
Industry
Eligibility
Not listed
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
27
States / cities
Phoenix, Arizona • Orange, California • Sacramento, California + 23 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 19, 2026, 10:48 PM EDT
Terminated No phase listed Observational

Study to Identify Markers of Insulin Resistance During Growth Hormone Treatment for Short Stature

NCT00121875
View directory record Official record
Conditions
Turner Syndrome, Idiopathic Short Stature
Interventions
somatropin (rDNA)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
7 Years to 14 Years · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 28, 2009 · Synced Sep 19, 2026, 10:48 PM EDT
Terminated Phase 4 Interventional Results available

A Pilot Study of Pre- and Post-operative Use of Somatuline Depot.

NCT01861717
View directory record Official record
Conditions
Acromegaly
Interventions
lanreotide
Drug
Lead sponsor
Saint John's Cancer Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Sep 29, 2021 · Synced Sep 19, 2026, 10:48 PM EDT
Completed No phase listed Observational

Effect of Growth Hormone (GH) on Cardiac Echos in GH Deficient Patients After Acromegaly Treatment

NCT01302652
View directory record Official record
Conditions
Acromegaly
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 17, 2015 · Synced Sep 19, 2026, 10:48 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Three Month Treatment of Growth Hormone Releasing Hormone (GHRH) in the Elderly

NCT01410799
View directory record Official record
Conditions
Hormone Deficiency, Aging
Interventions
Growth Hormone Releasing Hormone (GHRH )
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
65 Years and older
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 23, 2019 · Synced Sep 19, 2026, 10:48 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Four-Part Study to Assess the Safety, Tolerability, PK and PD of ONO-5788 in Healthy Adult Volunteers

NCT03571594
View directory record Official record
Conditions
Acromegaly
Interventions
ONO-5788, ONO-5788 Placebo, Octreotide
Drug
Lead sponsor
Ono Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 4, 2019 · Synced Sep 19, 2026, 10:48 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Abdominal Obesity, Cardiovascular Inflammation, and Effects of Growth Hormone Releasing Hormone Analogue

NCT01632592
View directory record Official record
Conditions
Abdominal Obesity
Interventions
Tesamorelin, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 23, 2014 · Synced Sep 19, 2026, 10:48 PM EDT
Terminated Phase 2 Interventional

Effects Of An Oral Growth Hormone Secretagogue In Older Functionally Limited Adults

NCT00527046
View directory record Official record
Conditions
Aging, Frail Older Adults
Interventions
CP-424,391
Drug
Lead sponsor
Pfizer
Industry
Eligibility
65 Years to 84 Years
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
12
States / cities
Palo Alto, California • San Diego, California • Hamden, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2012 · Synced Sep 19, 2026, 10:48 PM EDT
Completed Early Phase 1 Interventional

Low Dose Growth Hormone (GH) on Insulin Sensitivity and Cortisol Production Rates

NCT00517062
View directory record Official record
Conditions
Growth Hormone Deficiency
Interventions
Growth hormone (Genotropin), Placebo
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 2, 2012 · Synced Sep 19, 2026, 10:48 PM EDT